ADVISORY BOARD
PROF. TREVOR M. JONES
PHARMA R&D
CBE PhD Hon DSc FMedSci FRSC FRSM FKC Hon FRCP FFPM FBPharmacolS
Following a 20 year career at the Wellcome Trust, where he served as Director of R&D, Trevor is now on the Boards of e-Therapeutics, Arix Bioscience plc and is a visiting professor at King’s College, London. He also holds honorary degrees and Gold Medals from 6 universities. He has served on the World Health Organisation (WHO) Commission on Intellectual Property Rights, Innovation and Public Health (C.I.P.I.H) and was a member of the UK Government’s Medicines Commission. He contributed to the Human Genome project and was a member of the UK Prime Minister’s Task force on the Competitiveness of the Pharmaceutical Industry (PICTF) and Chair of the Government Advisory Group on Genetics Research.
For 10 years until September 2004, he was Director General of the Association of the British Pharmaceutical Industry (ABPI) a member of Council of IFPMA and the Board of EFPIA.
In 2005 he was the winner of the SCRIP Life Time Achievement award for his contribution to the pharmaceutical sciences and industry.
In 2016, Prof Jones was elected as a Fellow of The Academy of Medical Sciences (FMedSci) and in 2018 a Fellow of The Learned Society of Wales (FLSW)
He was honoured by Her Majesty Queen Elizabeth II by the award of CBE in the 2003 New Year's Honours List.
DR. T. (TEO) FORCHT DAGI
PUBLIC HEALTH
MD, MPH, MBA, DMedSc, DHC, FRCSEd
Teo is a neurosurgeon and neuro-intensivist, a veteran venture capitalist and board director with extensive international experience in public service. He has helped raise over $700 million in funds for portfolio companies and venture capital funds and has more than 15 years of successful experience in founding, managing and exiting companies in health care services and in the life sciences. He has operating experience in healthcare services, healthcare information technology and the biomedical sector, and he has served on boards of directors of publicly traded and privately held companies. He has also chaired or served on the scientific advisory boards of Dupont Pharma, Lundbeck, the Royal Bank of Canada and other private and publicly listed companies. He is also an editor of Neurosurgery, the Journal of Clinical Ethics, and Numanities, and has authored or co-authored over 175 articles and authored or edited several books.
Dr. Dagi serves as Distinguished Scholar and Professor at Queen’s University Belfast, Northern Ireland (UK), and a Scholar in the Academy at Harvard Medical School. He has lectured in the Harvard Business School on healthcare innovation and in the Biomedical Entrepreneurship Program at the Harvard-MIT Program in Health Sciences and Technology. He is Director of Life Sciences at Anglo Scientific at the Royal Institution of Great Britain.
DR MICHELLE TEMPEST
FINANCIAL ADVISOR
MA LLM MB BChir (Cantab) ACAT
Michelle has been a Partner at Candesic since 2013 and has led multiple projects reviewing market opportunities for investors, public and private providers to develop beneficial partnerships. She has delivered projects for NHS Trusts (acute, community and mental health), Private Hospitals, Specialist Hospitals, Private Patient Units (PPUs), Community Providers, Care Home and Care at Home. In 2006 she edited the book 'The Future of the NHS' and more recently has delivered strategy projects for the UK government on ‘new ways of working’. She has an expert interest in medical technology companies, and has worked with several MedTech companies on expansion plans and advised throughout the entire life cycle of deals. Previously Michelle worked as a hospital doctor and liaison psychiatrist for over a decade, and continues to lecture in 'medical ethics and law' at Cambridge University.
KATHY FARNDON
GENOMICS ADVISOR
FBCS, MIoD, MIHM
Kathy has held senior healthcare management roles in the UK, Canada and New Zealand. She was Head of Data and Information Governance at NHS England and led the data and informatics elements nationally for the 100,000 genome project. She is currently lending her experience to the Cross-Government Open Standards Board, is a member of the Health and Social Care Council for Tech UK and is a Director of the IT Health Partnership. Her expertise is in the design and implementation of healthcare information systems, strategy and health information governance. Her goal is to increase the effective use of technology to improve clinical decision-making. Kathy has a background in Medical Physics, specialising in cardiology.
JOHN PARKINSON
ONTOLOGY ADVISOR
BSc PhD FRSM
John is one of the leading experts in the use of data for public health and clinical studies. He was the Director of the Clinical Practice Research Datalink that was funded by the National Institute for Health Research. Under his leadership it grew rapidly to be the global database of choice of many regulators, academics and Pharma companies. He oversaw a massive IT change that dramatically improved the speed of data access and enabled GPRD to be widely record-linked to other UK NHS datasets. Prior to this John was expert advisor to the Connecting for Health/NIHR, Research Capability Programme that had major implications for further extending UK observational research and clinical trials
John is visiting Professor at the University of Leeds and is helping to develop the health data unit there. He also has strong links with NICOR, the National Institute for Cardiovascular Outcomes Research. His goal is to harness the power of linked real-world clinical data to improve individual health as well as the overall health of the nation and the NHS in both clinical trials and observational research.
GAVIN DAY
TECHNICAL ADVISOR
PhD
Gavin is our personal data sharing expert and has a long track record in developing ethical solutions for privacy centric cloud services and multi-platform client apps. He is currently Chief Product Officer for the Landmark Information Group and a Technical Advisor to digi.me, one of the platforms on which the Health Data Exchange is built. His career has also included technology leadership roles in major enterprises including AT&T and Cisco, as well as start-ups, Venture Capital and Private Equity M&A. Gavin partners with developer teams in the UK and Sarajevo to design and build the next generation of data consent and privacy management solutions which are GDPR and banking compliant to put everyone back in control of their own online data.
PETER BAINS
INDUSTRY ADVISOR
BSc Comb. (Hons) Physiology/Zoology
Peter Bains is a widely experienced biopharma executive with an over 30-year track record of leadership and achievement in building biopharma companies, businesses and brands. After 23 years with GSK, where held significant roles in General Management (China), strategy (Head of Global Marketing) and operations (SVP for International) he became CEO of Syngene, an Indian CRO, which he led and listed on the Mumbai stock exchange in 2015. In 2016 Peter became CEO of Sosei, a Japanese listed biotech company where he led the transformational acquisition of the UK biotech firm, Heptares Therapeutics, subsequently raising $200m in an institutional offering. Peter is currently a Director of MiNA Therapeutics, the sector-leading pioneer of small activating RNA therapeutics and Mereo Biopharma, a multi clinical stage biotech.
DR. NORMAN BEGG
RESEARCH ADVISOR
MBChB DTM&H FFPH
Dr Norman Begg is an independent vaccines consultant, with wide experience in the pharmaceutical industry (GSK) and the public sector. At GSK Vaccines from 2000 to 2018 he held several senior roles, including head of global clinical development (paediatric vaccines), head of scientific affairs and public health, and Chief Medical Officer. He is a public health physician who worked from 1984 to 2000 in the UK national public health institute, and as a regular consultant to the World Health Organisation. He has published extensively on the epidemiology, prevention and control of vaccine-preventable disease